MedTrace Logo

Twinrix Alternative Schedule Study

NCT00216229 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2005-12-14

No results posted yet for this study

Summary

To compare the efficiency of protection against hepatitis-B virus by administration of the combined vaccine against hepatitis A and B using the schedule 0-1-12 months against the schedule 0-1-6 months.

1. To compare the seroconversion (\>= 1 IU/l) and seroprotection (\>= 10 IU/l) rate at month 6,7,12 and 13.
2. To compare the distribution of anti-HBs at these different moments.

Conditions

  • Antibody Response After Vaccination

Interventions

BIOLOGICAL

Combined vaccine against hepatitis A and B (Twinrix)

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • IDEWE Occupational Health Services

    lead OTHER

Principal Investigators

  • Antoon A De Schryver, M.D., PhD · IDEWE Occupational Health Services

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2004-09-30
Completion
2006-02-28

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00216229 on ClinicalTrials.gov